Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
InsideTracker launched Terra, an AI platform that integrates wearable data, blood biomarkers, and health apps to deliver personalized recommendations for wellness and healthcare businesses. The shift reflects growing consumer demand for evidence-based outcomes rather than generic wellness claims, reshaping how the industry validates health interventions.
Rejuvenate Biomed has completed enrollment in a Phase 2 trial of RJx-01, a multi-pathway therapeutic targeting mitochondrial dysfunction and neuromuscular impairment in COPD-related sarcopenia. The drug showed improvements in muscle strength and fatigue resistance in prior Phase 1b data, with topline results expected by end of 2026.
Oura Ring 5 introduces hardware miniaturization with 40% size reduction and redesigned sensors alongside expanded software for continuous monitoring of breath, circulation, metabolic markers, and recovery. The device architecture addresses signal accuracy across diverse populations while integrating clinical data with daily biometric tracking.
Sunrise Air, an FDA-cleared rechargeable at-home sleep testing device, enables multi-night monitoring of sleep apnea through lightweight chin sensors and airflow tracking, addressing diagnostic barriers that delay identification of a condition affecting over 900 million people globally. Accurate, accessible sleep apnea diagnosis has become central to longevity medicine because chronic sleep disruption directly drives cardiovascular disease, metabolic dysfunction, and accelerated aging.
Sunrise Air, an FDA-cleared at-home sleep test that monitors mandibular jaw movement alongside respiratory sensors, enables multi-night testing without disposable components. The device applies AI algorithms to distinguish obstructive from central apneas, addressing diagnostic complexity in a condition affecting over 900 million people globally.
Insilico Medicine has advanced Rentosertib, an AI-designed TNIK inhibitor, into Phase 1 human trials for pulmonary fibrosis after demonstrating improved lung function and reduced fibrosis markers in preclinical studies. This represents a significant milestone for AI-driven drug discovery, with implications for accelerating therapeutic development in progressive fibrotic conditions.
HCW11-040, a pembrolizumab-derived immunotherapeutic, prevented bronchopulmonary dysplasia in preclinical models by eliminating oxygen-induced senescent cells and restoring exhausted immune function. This represents a potential first-in-class intervention for a rare pediatric lung disease affecting 10,000–15,000 U.S. infants annually, with IND filing anticipated in late 2027.
Moderate hyperoxia induces cellular senescence in developing airway tissue, with lasting consequences for lung function. Three mechanistically distinct interventions—Fucoidan, Dasatinib plus Quercetin, and MitoQ—each mitigate senescence through different pathways, offering potential strategies to prevent hyperoxia-related lung disease in premature infants.
Fine particulate matter (PM2.5) exposure drives cognitive decline and dementia incidence, with burden increasing substantially as populations age. Understanding how demographic shifts amplify PM2.5-related dementia risk across aging cohorts is essential for longevity strategy in rapidly aging societies.
Insilico Medicine obtained investigational new drug clearance for an inhaled formulation of rentosertib, a TNIK inhibitor discovered through AI-driven drug discovery, designed to deliver targeted lung exposure in idiopathic pulmonary fibrosis. The inhalation route enables higher local bioavailability at lower systemic doses, advancing a potential therapeutic for a progressive fibrotic lung condition.
The Super Age Games reframe competitive fitness around healthspan—the quality and sustainability of functional life—rather than isolated performance metrics. This shifts how populations measure aging success, integrating physical, cognitive, metabolic, and social dimensions into a single assessment model that reflects real-world health integration.
Calluna Pharma has completed enrollment in a Phase 2 trial of CAL101, a monoclonal antibody targeting S100A4 to preserve lung function in idiopathic pulmonary fibrosis, a disease with median survival of 3-5 years. Topline results are expected in Q1 2027.